Skip to main content
Equibles
BMRA logo

BMRA · Biomerica Inc · Metrics

Track BMRA — free

Use BMRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BMRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.71 -0.01 (-0.51%) At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Oct 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the issuance date of these financial statements. Our future viability depends on the successful execution of our strategic plans, securing additional near-term financing, and achieving profitable operations.”
View the 10-Q filed Oct 15, 2026
Market Cap
$7.86M
Shares
4.60M
Volume · Oct 21 7547 Avg daily vol (3M) 70.76K

BMRA metrics

84 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.71
Market cap
$7.86M

Price action

20 metrics
Price change (1W)
-7.1%
Price change (30D)
-33.9%
Price change (3M)
+4.8%
Price change (6M)
-20.4%
Price change (YTD)
-31.8%
Price change (1Y)
-44.9%
Trailing year
Price change (5Y)
—
52-week high
$3.20
52-week low
$1.49
Change from 52-week high
-46.3%
Change from 52-week low
+15.3%
Annualized volatility
58.5%
Annualized volatility (3M)
75.3%
Beta
0.8
RSI (14D)
33.8
Price vs SMA 50
-15.8%
Price vs SMA 200
-17.7%
Avg volume (3M)
70,677
Relative volume
0.1
Average dollar volume
$149,673

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
4.60M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.8×
reciprocal yield 54.9%
P / book
2.2
reciprocal yield 46.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-63.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.3×
reciprocal yield 79.1%
EV / revenue historical average (5Y)
2.5×
reciprocal yield 39.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
0.9%
Operating margin
-125.1%
Trailing 12 months
Net margin
-115.5%
Gross profit (TTM)
$41,000
Operating profit (TTM)
−$5.43M
Net income (TTM)
−$5.01M
Trailing 12 months
Diluted EPS (TTM)
$-1.67
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.41
Gross profit per diluted share (TTM)
$0.01
Operating profit per diluted share (TTM)
$-1.77
EBITDA per diluted share (TTM)
$-1.75
Net income per diluted share (TTM)
$-1.63
Operating cash flow per diluted share (TTM)
$-1.29
Free cash flow per diluted share (TTM)
$-2.57
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$0.25
Stock compensation per diluted share (TTM)
$0.16
Book value per share
$0.82

Growth

11 metrics
Revenue growth YoY
-8.3%
Year over year
Net income growth YoY
-61,700.0%
Revenue (TTM)
$4.34M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+24.9%
Year over year · more shares
Revenue CAGR (3Y)
-5.9%
Revenue CAGR (5Y)
-9.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-137.3%
Return on assets
-62.1%
Debt / equity
—
Current ratio
1.9
EBITDA (TTM)
−$5.36M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$2.73M
Latest balance sheet
Cash & equivalents
$2.73M
Total assets
$8.07M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.96M
Capital expenditures (TTM)
$51,000
R&D (TTM)
$782,000
SG&A (TTM)
$4.69M
Stock compensation (TTM)
$477,000
R&D / revenue
18.0%
Stock compensation / revenue
11.0%

Ownership (13F)

9 metrics
13F filers
20
13F filer change QoQ
+9
Institutional ownership
2.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.3%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+283.7%
Holder tenure
8.2
Price vs estimated holder cost
-20.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.4%

Short interest

3 metrics
Short interest
0.6%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
25 / 100

Insider activity

2 metrics
Net insider buying (90D)
$158,000
Insider-sentiment score
93 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 73290 CUSIP 09061H406 Visit website Investor relations